Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03OQI
|
||||
| Former ID |
DIB013933
|
||||
| Drug Name |
Tozadenant
|
||||
| Synonyms |
Ro-2; SYN-115; A2a receptor antagonists (Parkinson's disease), Synosia/Roche; Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 3 | [1], [2] | ||
| Company |
Biotie therapies
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H26N4O4S
|
||||
| InChI |
InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
|
||||
| InChIKey |
XNBRWUQWSKXMPW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 870070-55-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16721298, 23726919, 75973556, 135257958, 135626892, 136988949, 141557752, 152258294, 160647133, 160687242, 160832419, 162011685, 163095493, 163397653, 163844113, 170500072, 174531109, 178102245, 198983564, 204390923, 223388041, 223573731, 225375928, 227819121, 242057800, 248681534, 251963261, 252479041, 252820044
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2a receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | NGF-independant TRKA activation | ||||
| Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02453386) Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5611). | ||||
| REF 3 | Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.